Biopharmaceutical company (acquired)
Appears in 1 story
Wholly owned by Genmab after $8 billion deal
Genmab's experimental head and neck cancer drug cut the risk of death in half in a late-stage trial, sending the Danish drugmaker's stock to an all-time high. The result is the company's third straight late-stage win in under a month.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
